FLT3 and acute myeloid leukemia: In a phase II trial of sorafenib and azacytidine in 43 patients (37 evaluable) with FLT3-mutated AML and 0–7 (median 2) prior therapies, the ORR was 46%, including 27% CR/CRi [31].